141 related articles for article (PubMed ID: 27774839)
1. Differences in Brain Glucose Metabolism During Preparation for
Jeong HS; Choi EK; Song IU; Chung YA; Park JS; Oh JK
Thyroid; 2017 Jan; 27(1):23-28. PubMed ID: 27774839
[TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
3. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study.
Constant EL; de Volder AG; Ivanoiu A; Bol A; Labar D; Seghers A; Cosnard G; Melin J; Daumerie C
J Clin Endocrinol Metab; 2001 Aug; 86(8):3864-70. PubMed ID: 11502825
[TBL] [Abstract][Full Text] [Related]
4. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy.
Bauer M; Silverman DH; Schlagenhauf F; London ED; Geist CL; van Herle K; Rasgon N; Martinez D; Miller K; van Herle A; Berman SM; Phelps ME; Whybrow PC
J Clin Endocrinol Metab; 2009 Aug; 94(8):2922-9. PubMed ID: 19435829
[TBL] [Abstract][Full Text] [Related]
5. Abnormal Brain Glucose Metabolism in Papillary Thyroid Cancer Patients 4 Weeks After Withdrawal of Levothyroxine: A Cross-Sectional Study Using
Wu SQ; Feng F; Zou RJ; Fu HL; Sun JW; Jia XZ; Yin YF; Wang H
Front Endocrinol (Lausanne); 2021; 12():595933. PubMed ID: 33776909
[TBL] [Abstract][Full Text] [Related]
6. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders.
Marangell LB; Ketter TA; George MS; Pazzaglia PJ; Callahan AM; Parekh P; Andreason PJ; Horwitz B; Herscovitch P; Post RM
Am J Psychiatry; 1997 Feb; 154(2):224-30. PubMed ID: 9016272
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
8. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma.
Luster M; Sherman SI; Skarulis MC; Reynolds JR; Lassmann M; Hänscheid H; Reiners C
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1371-7. PubMed ID: 12856155
[TBL] [Abstract][Full Text] [Related]
11. TSH suppression aggravates arterial inflammation - an
Boswijk E; Sanders KJC; Broeders EPM; de Ligt M; Vijgen GHEJ; Havekes B; Mingels AMA; Wierts R; van Marken Lichtenbelt WD; Schrauwen P; Mottaghy FM; Wildberger JE; Bucerius J
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1428-1438. PubMed ID: 30859432
[TBL] [Abstract][Full Text] [Related]
12. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
13. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM
J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836
[TBL] [Abstract][Full Text] [Related]
14. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
Rosario PW; Calsolari MR
Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
[TBL] [Abstract][Full Text] [Related]
15. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
Ladenson PW; Braverman LE; Mazzaferri EL; Brucker-Davis F; Cooper DS; Garber JR; Wondisford FE; Davies TF; DeGroot LJ; Daniels GH; Ross DS; Weintraub BD
N Engl J Med; 1997 Sep; 337(13):888-96. PubMed ID: 9302303
[TBL] [Abstract][Full Text] [Related]
16. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
18. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
19. Diminished Quality of Life and Increased Brain Functional Connectivity in Patients with Hypothyroidism After Total Thyroidectomy.
Shin YW; Choi YM; Kim HS; Kim DJ; Jo HJ; O'Donnell BF; Jang EK; Kim TY; Shong YK; Hong JP; Kim WB
Thyroid; 2016 May; 26(5):641-9. PubMed ID: 26976233
[TBL] [Abstract][Full Text] [Related]
20. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer.
Coura-Filho GB; Willegaignon J; Buchpiguel CA; Sapienza MT
Thyroid; 2015 Dec; 25(12):1291-6. PubMed ID: 26446582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
